NAMD Urges Medicare to Not to Shift Cost of Alzheimer’s Drug to Medicaid
On August 11, 2021, NAMD sent a letter to CMS asking that Medicare not shift the cost of the new Alzheimer’s drug Aduhelm onto state Medicaid programs. If Medicare chooses to not cover Aduhelm, Medicaid spending on these therapies may grow by up to 250% nationally.
On June 7, 2021, the FDA granted accelerated approval to a new Alzheimer’s drug called Aduhlem (or its generic name, aducanumab). The list price for this product is $56,000 per year, and there has been significant debate in the scientific community over the efficacy of this medication. Currently, Medicare is going through a National Coverage Determination process to decide whether they will cover this drug. If Medicare chooses not to cover Aduhelm, state Medicaid programs will be required to cover it per the Medicaid Drug Rebate Program, which could result in large spending increases for states.
NAMD sent a letter to CMS requesting that they take steps to mitigate this spending risk for states. Specifically, CMS could require Medicare to cover Adulhelm. Alternatively, HHS could add Aduhlem to the list of drugs that can receive restricted coverage under the Medicaid Drug Rebate Program. This would give states the same flexibility available to other payers to scale back or pause coverage until more reliable evidence of efficacy emerges.
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
NAMD Comments on Proposed Medicare Special Enrollment Periods and Savings Program Changes
Drop us your email and we’ll keep you up-to-date on Medicaid issues.